HMNC Pushes On With Biomarker-Driven Depression Drug After Setback

Company Refines Genetic Tool, Eyes Phase III Despite Phase II Miss

 
• By Sushmita Panda
  
Hans Eriksson, chief medical officer at HMNC Brain Health
Photograph of Hans Eriksson, chief medical officer at HMNC Brain Health
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Clinical Trials

More from R&D